O-3-methylglutaryl-L-carnitine

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: O-3-methylglutaryl-L-carnitine
• 英文别名: (3R)-3-(4-carboxy-3-methylbutanoyl)oxy-4-(trimethylazaniumyl)butanoate
• 化学式: C13H23NO6
• 分子量: 289.32
• InChiKey: HFCPFJNSBPQJDP-QVDQXJPCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  20
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  104
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Methods and systems for metabolite and/or lipid-based detection of colorectal cancer and/or adenomatous polyps
  申请人：Universal Diagnostics, S.L.

  公开号：US10006925B2

  公开（公告）日：2018-06-26

  Described herein are sets of metabolite and lipid (e.g., fatty acid) markers that can be used in the detection of early stage colorectal cancer and/or early development of adenomatous polyps. Presented herein are illustrative pathology-linked panels. In certain embodiments, the markers presented herein (or subsets thereof) are used as a panel for detecting either colorectal cancer or adenomatous polyps at the same time. The markers presented herein include metabolites and lipids (e.g., fatty acid) freely detectable and accurately quantifiable in human serum. In certain embodiments, the sample may be plasma, urine, saliva, whole blood, dried blood spot or dried serum spot.

  本文介绍了可用于检测早期结直肠癌和/或早期腺瘤性息肉的代谢物和脂质（如脂肪酸）标记物。本文介绍的是与病理学相关的说明性面板。在某些实施方案中，本文提出的标记物（或其子集）可用作同时检测结直肠癌或腺瘤性息肉的面板。本文提出的标记物包括可在人体血清中自由检测和准确量化的代谢物和脂质（如脂肪酸）。在某些实施方案中，样本可以是血浆、尿液、唾液、全血、干血斑或干血清斑。
• METHODS AND SYSTEMS FOR METABOLITE AND/OR LIPID-BASED DETECTION OF COLORECTAL CANCER AND/OR ADENOMATOUS POLYPS
  申请人：Universal Diagnostics, S.L.

  公开号：US20170343567A1

  公开（公告）日：2017-11-30

  Described herein are sets of metabolite and lipid (e.g., fatty acid) markers that can be used in the detection of early stage colorectal cancer and/or early development of adenomatous polyps. Presented herein are illustrative pathology-linked panels. In certain embodiments, the markers presented herein (or subsets thereof) are used as a panel for detecting either colorectal cancer or adenomatous polyps at the same time. The markers presented herein include metabolites and lipids (e.g., fatty acid) freely detectable and accurately quantifiable in human serum. In certain embodiments, the sample may be plasma, urine, saliva, whole blood, dried blood spot or dried serum spot.